Provided by Tiger Trade Technology Pte. Ltd.

RenovoRx Inc

1.32
0.0000
Post-market: 1.31-0.0100-0.76%19:30 EDT
Volume:233.27K
Turnover:301.54K
Market Cap:59.47M
PE:-4.26
High:1.33
Open:1.30
Low:1.25
Close:1.32
52wk High:1.51
52wk Low:0.7006
Shares:45.05M
Float Shares:39.17M
Volume Ratio:0.32
T/O Rate:0.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3096
EPS(LYR):-0.3161
ROE:-125.23%
ROA:-64.90%
PB:6.62
PE(LYR):-4.18

Loading ...

RenovoRx - Raises Full-Year 2026 Revenue Guidance to $3.75 Mln-$4.25 Mln

THOMSON REUTERS
·
Aug 13

RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth

THOMSON REUTERS
·
Aug 13

RenovoRx - Trial Completion Expected H1 2027; Top Line Data Expected H2 2027

THOMSON REUTERS
·
Aug 11

RenovoRx Inc Expected to Post a Loss of 7 Cents a Share - Earnings Preview

Reuters
·
Aug 11

RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors

GlobeNewswire
·
Aug 06

RenovoRx Highlights TAMP Platform in Upcoming Oncology Webinar

TIPRANKS
·
Aug 05

RenovoRx Joins JonesTrading Webinar on TAMP Platform in Pancreatic Cancer

Reuters
·
Aug 04

RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET

GlobeNewswire
·
Jul 29

RenovoRx, Inc. (NASDAQ:RNXT): Are Analysts Optimistic?

Simply Wall St.
·
Jul 28

RenovoRx Granted Extended Nasdaq Compliance Period Amid Listing Risk

TIPRANKS
·
Jul 02

Renovorx Wins NASDAQ Extension to Regain $1 Minimum Bid Compliance

Reuters
·
Jul 02

RenovoRx Stockholders Approve Directors and Equity Plan

TIPRANKS
·
Jul 01

Renovorx Holds Annual Shareholder Meeting

Reuters
·
Jul 01

RenovoRx highlights case study on intra-arterial gemcitabine delivery via TAMP in pancreatic cancer

Reuters
·
Jun 11

RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer

GlobeNewswire
·
Jun 11

RenovoRx CEO Shaun Bagai presents at iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026

Reuters
·
Jun 04

RenovoRx Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Jun 01

RenovoRx says FDA grants orphan drug designation for oxaliplatin in pancreatic cancer

Reuters
·
May 28

RenovoRx - Odd Provides Seven Years of Market Exclusivity Upon FDA Approval

THOMSON REUTERS
·
May 28

RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer

THOMSON REUTERS
·
May 28